Johnson & Johnson’s strong track record of beating adjusted EPS estimates, combined with raised full-year 2026 guidance after solid Q2 results, underpins the 84.5% market-implied probability of a Q3 beat. Operational sales grew 5.6% year-over-year in the prior quarter to $25.31 billion, fueled by oncology and immunology products such as Darzalex and Tremfya, while the company lifted its adjusted EPS midpoint to $11.68. Recent positive clinical data on Tremfya and Carvykti have reinforced pipeline momentum ahead of the October 13 release. Although in-process R&D charges may pressure GAAP figures and some analysts project a modest miss on adjusted metrics, traders appear to discount one-time items and price in the likelihood of another consensus beat given historical patterns and sector stability.